Cargando…

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma

AIMS: Anti-angiotherapy (Bevacizumab) is currently regarded as a promising option for glioma patients who are resistant to temozolomide (TMZ) treatment. But ongoing clinical research failed to meet therapeutic expectations. This study aimed to explore the pivotal genetic feature responsible for TMZ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Ying, Wu, Mengwan, Liu, Yuyang, Hu, Lanlin, Wu, Hong, Xie, Lei, Liu, Zhiwei, Wu, Anhua, Chen, Ling, Xu, Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719456/ https://www.ncbi.nlm.nih.gov/pubmed/34976814 http://dx.doi.org/10.3389/fonc.2021.769592

Ejemplares similares

Comprehensive analysis of HHV‐6 and HHV‐7‐related gene signature in prognosis and response to temozolomide of glioma
por: Chen, Luoyi, et al.
Publicado: (2022)

ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
por: Li, Shuyu, et al.
Publicado: (2022)

Hypoxia‐induced polypoid giant cancer cells in glioma promote the transformation of tumor‐associated macrophages to a tumor‐supportive phenotype
por: Liu, Yuyang, et al.
Publicado: (2022)

Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p
por: Li, Haoyu, et al.
Publicado: (2021)

The strategy for enhancing temozolomide against malignant glioma
por: Nakada, Mitsutoshi, et al.
Publicado: (2012)

FEV Maintains Homing and Expansion by Activating ITGA4 Transcription in Primary and Relapsed AML
por: Zhang, Jubin, et al.
Publicado: (2022)

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis
por: Hu, Zhifang, et al.
Publicado: (2020)

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
por: Daniel, Paul, et al.
Publicado: (2019)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis
por: Wang, Huan, et al.
Publicado: (2021)

Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma
por: Chakravarty, Malobika, et al.
Publicado: (2021)

Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas
por: Gu, Qiang, et al.
Publicado: (2023)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription
por: Ye, Xiang, et al.
Publicado: (2021)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT
por: Zhang, Qing, et al.
Publicado: (2020)

Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma
por: Zhang, Guoliang, et al.
Publicado: (2022)

The Effect of Temozolomide/Poly(lactide-co-glycolide) (PLGA)/Nano-Hydroxyapatite Microspheres on Glioma U87 Cells Behavior
por: Zhang, Dongyong, et al.
Publicado: (2012)

TERT Promoter Mutations Lead to High Transcriptional Activity under Hypoxia and Temozolomide Treatment and Predict Poor Prognosis in Gliomas
por: Chen, Chen, et al.
Publicado: (2014)

miR-9-5p Mediates ABCC1 to Elevate the Sensitivity of Glioma Cells to Temozolomide
por: Chen, Xiang-Rui, et al.
Publicado: (2021)

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
por: Shi, Hui, et al.
Publicado: (2020)

METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m(6)A Dependent Manner
por: Shi, Jia, et al.
Publicado: (2021)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

ITGA3 Is Associated With Immune Cell Infiltration and Serves as a Favorable Prognostic Biomarker for Breast Cancer
por: Li, Yue, et al.
Publicado: (2021)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway
por: Tsai, Hong-Chieh, et al.
Publicado: (2021)

Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment
por: Xue, Wei, et al.
Publicado: (2017)

Expression and Prognostic Analyses of ITGA3, ITGA5, and ITGA6 in Head and Neck Squamous Cell Carcinoma
por: Feng, Chen, et al.
Publicado: (2020)

Temozolomide – Just a Radiosensitizer?
por: Kaina, Bernd, et al.
Publicado: (2022)

Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy
por: Hu, Li, et al.
Publicado: (2021)

Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4
por: Xu, Qun, et al.
Publicado: (2022)

Differential Characterization of Temozolomide-Resistant Human Glioma Cells
por: Lai, Sheng-Wei, et al.
Publicado: (2018)

Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways
por: Meng, Xiangqi, et al.
Publicado: (2020)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

Ferroptosis in glioma treatment: Current situation, prospects and drug applications
por: Zhou, Yuhang, et al.
Publicado: (2022)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide
por: Bota, Daniela A., et al.
Publicado: (2022)

Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity
por: Shi, Ping, et al.
Publicado: (2022)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i7siibr75mcisli5348o9rmb7e